SANSERT
LOE ApproachingNDAORALTABLETPriority Review
Approved
Feb 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SANSERT is an oral small-molecule tablet approved in 1962 by Novartis for an undisclosed indication. The specific mechanism of action and therapeutic use are not publicly detailed in available data, limiting characterization of its clinical role.
LOE Approaching
This legacy product faces approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a contracting commercial organization focused on managed decline and cost control.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SANSERT currently shows zero linked job openings, reflecting a legacy product with minimal hiring momentum. Career opportunities on this asset are limited and primarily focused on maintaining existing market presence rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on SANSERT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.